Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2008

View Archived Issues

Indibulin well tolerated, active in patients with advanced solid tumors

DTS-108 may represent an improvement over irinotecan

Abacavir, didanosine linked to increased risk of myocardial infarction

Nebicapone increases levodopa exposure in Parkinson's disease patients

PHX-1149 effective in proof-of-concept study in type 2 diabetes patients

Collegium filed supplemental NDA for approval of AllerNase for allergic rhinitis

Phase I study of ENMD-2076 begins in advanced cancer patients

Otelixizumab set to enter phase III for new-onset type 1 diabetes

Cationorm launched in France for dry eye symptoms

Novel CGRP antagonist profiled at Merck & Co.

Iomai receives grant to develop patch-based anthrax vaccine

Critical Therapeutics completes phase I clinical trial of (R)-zileuton

Exubera labeling updated in the United States

Seattle Genetics initiates phase Ib clinical trial of SGN-40 in non-Hodgkin's lymphoma

Novartis' ACZ-885 shows potential in treating serious life-long autoinflammatory conditions

Teverelix LA demonstrates testosterone suppression in prostate cancer study

BGC-20-0166 shows potential for obstructive sleep apnea

OVax cleared to begin phase I/II trial in ovarian cancer

Aerosolized ALN-RSV01 begins phase II trial in adult RSV

Pivotal phase III trial commences for novel cancer agent ASA-404

FDA approves Lexiscan as an agent in myocardial perfusion imaging

Crucell enters research license agreement with Celltrion to evaluate Star production technology

FDA extends action date for priority review of Amgen's BLA for romiplostim in ITP

Recent patents disclose novel antidiabetic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...